Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

Journal of the National Cancer Institute

Volumn 83, Issue 11, 1991, Pages 757-766

  Monks, Anne ^a,b   Scudiero, Dominic ^a,b   Skehan, Philip ^a,b   Shoemaker, Robert ^a,b   Paull, Kenneth ^a,b   Vistica, David ^a,b   Hose, Curtis ^a,b   Langley, John ^a,b   Cronise, Paul ^a,b   Vaigro wolff, Anne ^a,b   Gray goodrich, Marcia ^a,b   Campbell, Hugh ^a,b   Mayo, Joseph ^a,b   Boyd, Michael ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MELPHALAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SPECTROPHOTOMETRY; TUMOR CELL LINE;

CELL DIVISION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; QUALITY CONTROL; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0025775062     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/83.11.757     Document Type: Article

References (15)

1. Boyd MR: National Cancer Institute drug discovery and development. In Accomplishments in Oncology. Cancer Therapy: Where Do We Go From Here? (Frei EJ, Freireich EJ, eds), vol 1, No. 1. Philadelphia: Lippincott, 1986, pp 68–76
2. Boyd MR, Shoemaker RH, McLemore TL, et al: New drug development. In Thoracic Oncology (Roth JA, Ruckdeschel JC, Weisenburger TH, eds), chap 49. Philadelphia: Saunders, 1989, pp 711–721
3. Boyd MR: Status of the National Cancer Institute preclinical antitumor drug discovery screen: Implications for selection of new agents for clinical trial. In Cancer Principles and Practice of Oncology Update (DeVita VT, Jr, Heilman S, Rosenberg SA, eds), vol 3, No. 10. Philadelphia: Lippincott, 1989, pp 1–12
4. Alley MC, Scudiero DA, Monks A, et al: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589–601, 1988
5. Scudiero DA, Shoemaker RH, Paull KD, et al: Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827–4833, 1988
6. Skehan P, Storeng R, Scudiero DA, et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112, 1990
7. Stinson SF, Alley MC, Kenney S, et al: Morphologic characterization of human cell carcinoma cell lines. Presented at the annual meeting of the American Association for Cancer Research, San Francisco, Calif, May 2427, 1989
8. Skehan P: On the normality of growth dynamics of neoplasms in vivo: Data base analysis. Growth 50:496–515, 1986
9. Vistica DT, Skehan P, Scudiero DA, et al: Tetrazolium-based assays for cellular viability: A critical examination of parameters which affect for-mazan production. Cancer Res. In press
10. Vistica DT, Scudiero DA, Skehan P, et al: New carbon dioxide-independent basal growth medium for culture of diverse tumor and nontumor cells of human and nonhuman origin. J Natl Cancer Inst 82:1055–1061, 1990
11. Rubinstein LV, Paull KD, Shoemaker RH, et al: Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113–1118,1990
12. Ad Hoc Review Committee: Proceedings for National Cancer Institute In Vitro/In Vivo Disease-Oriented Screening Project. Bethesda, Md: NIH, Nov 13–15,1989
13. Reviewers Report Progress in New Drug Prescreen System Development. Cancer Lett 15:1–5, 1989
14. Boyd MR, Paull KD, Rubenstejn LR: Data display and analysis strategies for the NCI disease-oriented in vitro antitumor drug screen. In Proceedings of the 22nd Annual Detroit Oncology Symposium on Anticancer Drug Discovery and Development (Valeriote FA, Corbett T, Baker L, eds). Detroit, April 25–27, 1990
15. Paull KD, Shoemaker RH, Hodes L, et al: Display and analysis of patterns of differential activity of drugs against human tumor cell lines. J Natl Cancer Inst 81:1088–1092, 1989